5 Results for "

Slowing down aging

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Slowing down aging" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-107811
CAS No.: 487-03-6
Purity:  99.76%
Harmol is an orally active β-carboline alkaloid. Harmol is a TFEB activator and monoamine oxidase inhibitor. Harmol can induce cell mitosis, Autophagy and Apoptosis. Harmol promotes the degradation of α-synuclein by regulating the autophagy-lysosomal pathway. Harmol has anti-tumor, anti-depressant and anti-aging activities. Harmol improves motor impairment in a mouse Parkinson's disease model .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-15114
CAS No.: 176797-26-5
Purity:  99.78%
Synonyms: S 17092-1
S 17092 (S 17092-1) is an orally active cerebral prolyl-endopeptidase (PEP) inhibitor with an IC50 of 1.2 nM. S 17092 inhibits cell apoptosis. S 17092 mechanism of action is to inhibit the activity of PEP, slowing down the degradation of neuroactive peptides and thus enhancing memory function. S 17092 can be used for the research of memory impairment and cognitive disorders associated with cerebral aging .
loading...
    loading...
Cat. No.: HY-W337672
CAS No.: 18684-24-7
Synonyms: Prolylhydroxyproline; Pro-Hyp
Research Areas:  

Others

H-Pro-Hyp-OH is a collagen peptide composed of proline (Pro) and hydroxyproline (Hyp). H-Pro-Hyp-OH can be used in research on slowing down facial aging .
loading...
    loading...
Cat. No.: HY-P991886

Target:  

Complement System

Research Areas:  

Neurological Disease

ANX-M1 is a blood-brain barrier-permeable anti-C1q antibody. ANX-M1 can slow down the progression of retinal degeneration following photo-oxidative damage. ANX-M1 has been incorporated into nanocarriers to evaluate its brain delivery efficacy in a mouse model of Alzheimer's disease. ANX-M1 is applicable for research on age-related macular degeneration and Alzheimer's disease [1] .
loading...
    loading...
Cat. No.: HY-L085
2,146 compounds

Parkinson’s disease (PD), the second most common age-associated neurodegenerative disorder, is characterized by the loss of dopaminergic (DA) neurons and the presence of α-synuclein-containing aggregates in the substantia nigra pars compacta (SNpc). Motor features such as tremor, rigidity, bradykinesia and postural instability are common traits of PD. To date, there is no treatment to stop or at least slow down the progression of the disease. The etiology and pathogenesis of PD is still elusive, however, a large body of evidence suggests a prominent role of oxidative stress, inflammation, apoptosis, mitochondrial dysfunction and proteasome dysfunction in the pathogenesis of PD.

MCE offers a unique collection of 2,146 compounds with anti- Parkinson’s Disease activities or targeting the unique targets of PD. MCE Anti- Parkinson's Disease Compound Library is a useful tool for exploring the mechanism of PD and discovering new drugs for PD.